DHA (docosahexaenoic acid) makes up roughly 30% of the brain's grey matter. Low DHA status is consistently associated with cognitive decline, depression, and dementia risk. Here is what the evidence says about supplementation.
For educational purposes only — not medical advice. How we evaluate evidence →
Reviewed by
Dr. A. Ferreira, MDGeneral practitioner with integrative medicine training. Reviewed for factual accuracy. This article is for educational purposes only and does not constitute medical advice.
Last reviewed
This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making health decisions. Our editorial standards →
The brain is approximately 60% fat by dry weight, and the most abundant structural fat in the brain is DHA — docosahexaenoic acid, a long-chain omega-3 fatty acid. DHA makes up roughly 30% of the fatty acids in the brain's grey matter and is particularly concentrated in the synaptic membranes where neurons communicate. It is essential for membrane fluidity, synaptic plasticity, and the production of neuroprotective compounds called neuroprotectins. The brain cannot synthesise DHA in meaningful quantities — it must be obtained from the diet or supplementation. The primary dietary sources are fatty fish (salmon, sardines, mackerel, herring), seafood, and algae (the original source of DHA in the marine food chain, and the basis of algae-based omega-3 supplements).
DHA Status and Cognitive Decline. Multiple large observational studies have found that low blood DHA levels are associated with accelerated cognitive aging and increased dementia risk. The Framingham Heart Study found that individuals in the lowest quartile of DHA status had a 47% higher risk of all-cause dementia compared to those in the highest quartile (Schaefer et al., Archives of Neurology, 2006). The PREDIMED-Plus trial found that higher adherence to a Mediterranean diet — rich in omega-3 from fish and olive oil — was associated with slower cognitive decline over 3 years. These are observational associations; they establish correlation but not causation.
Supplementation Trials: A Mixed Picture. The RCT evidence for omega-3 supplementation and cognitive outcomes is more mixed than the observational data suggests. The MIDAS trial (Yurko-Mauro et al., Alzheimer's & Dementia, 2010) found that 900mg/day of algal DHA for 24 weeks significantly improved learning and memory in 485 healthy older adults with age-related cognitive decline. The OMEGA-AD trial found no benefit of omega-3 supplementation in patients with established Alzheimer's disease — suggesting that DHA may be more relevant to prevention than treatment of advanced disease. The VITACOG trial found that B vitamins reduced brain atrophy in people with MCI, but only in those with high omega-3 status — suggesting a synergistic interaction. The overall picture: DHA supplementation appears most beneficial for prevention and early-stage cognitive decline, particularly in people with low baseline intake.
The evidence for omega-3 in depression is stronger than for dementia. A 2019 meta-analysis of 26 RCTs (Liao et al., Translational Psychiatry) found that omega-3 supplementation significantly reduced depressive symptoms, with EPA (eicosapentaenoic acid) appearing more effective than DHA for mood. The proposed mechanisms include reduced neuroinflammation, modulation of serotonin and dopamine signalling, and improved membrane fluidity in limbic system neurons. The American Psychiatric Association has recommended omega-3 supplementation as an adjunct treatment for depression, particularly for patients who do not fully respond to antidepressants.
Practical Guidance: Dose, Form, and Sources. For general brain health maintenance: 1–2g/day of combined EPA+DHA from fish oil or algal oil. For cognitive support in older adults or those with low fish intake: 2–3g/day DHA-dominant formula. For depression: 1–2g/day EPA-dominant formula (EPA:DHA ratio of at least 2:1). Algal oil is the preferred form for vegetarians, vegans, and those concerned about fish sustainability — it provides DHA directly without the conversion inefficiency of ALA from flaxseed. Fish oil quality matters: look for products that are third-party tested for oxidation (TOTOX score) and heavy metals. Store in the refrigerator after opening. The most efficient dietary sources: wild salmon (2g omega-3 per 100g), sardines (1.5g/100g), mackerel (2.5g/100g), and herring (1.7g/100g).
Personalised plan
Get a personalised brain health and cognitive care plan.
Seen a claim you want to verify?
The Claim Decoder grades the evidence behind any natural health claim — A to F, with sources.
Suggested from this article:
"Lion's mane mushroom stimulates nerve growth factor in humans"
Prompted by: Omega-3 DHA and Brain Health: The Evidence for Cognitive Protection
The MIND diet reduces Alzheimer's risk by up to 53% in adherent individuals. Here is what the evidence says about food, brain aging, and cognitive decline — and the practical eating pattern that protects the most.
Omega-3s, lion's mane, phosphatidylserine, B vitamins, and vitamin D all have research behind them for cognitive health. Here is an honest look at what the evidence actually supports — and what it does not.
Regular aerobic exercise reduces dementia risk by 30–40% in large cohort studies. A landmark twin study found leg-focused resistance training produced a 47% improvement in cognitive performance. It also grows the hippocampus, increases BDNF, and clears amyloid. Here is the evidence — and the minimum effective dose.
